TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMA

TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMA - TARC IN PATIENTS WITH LYMPHADENOPATH, FEVER OR NON-HODGKIN LYMPHOMA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45645

Enrollment

300

Registered

2017-04-13

Start date

2017-05-17

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

andere ziekten gepaard met lymfeklier vergroting Fever lymph node enlargment lymphoma

Interventions

Diagnostic

Hodgkin

Lymphadenopathy

TARC

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age * 18 years; - Ability to give written informed consent; And one of the following: (1) Lymph node enlargement of unknown cause for whicha diagnostic fine needle aspiration will be performedor (2) Presenting with fever at the emergency department or (3) Presenting with newly diagnosed or relapsed nodular lymphocyte predominant or non-Hodgkin lymphoma.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study (applicable to all subgroups): - Ineligibility to give written informed consent; - Patients with active atopic disease or hepatic failure; - Patients already diagnosed with Hodgkin lymphoma

Design outcomes

Primary

Measure	Time frame
Mean TARC levels (pg/mL) in correlation with final diagnosis.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)